Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JNJ-26483327
- Development stage
- Phase 1
- Lead developer
- Johnson & Johnson Pharmaceutical Research & Development LLC
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
JNJ-26483327 is an orally bioavailable, small-molecule multitargeted tyrosine kinase inhibitor developed primarily for oncology indications. It inhibits several members of the epidermal growth factor receptor (EGFR) family (including EGFR/ERBB1, HER2/ERBB2, and HER4/ERBB4), Src family kinases (Lyn, Yes, Fyn, Lck and Src), vascular endothelial growth factor receptor 3 (VEGFR3), and RET. By targeting these kinases involved in tumorigenesis and angiogenesis pathways, JNJ-26483327 may inhibit tumor cell proliferation, invasion/migration and metastasis. The drug has demonstrated the ability to cross the blood-brain barrier. Developed by Janssen Pharmaceutica (a subsidiary of Johnson & Johnson), it reached phase I clinical trials for advanced solid tumors but no further development has been reported[1][2][5][7].
- Other names
- 807640-87-5UNII-16720VER1HUNII16720VER1HUNII 16720VER1H
02
Targets
EGFR (Epidermal growth factor receptor)FLT3 (Fms related receptor tyrosine kinase 3)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB4 (Erb-b2 receptor tyrosine kinase 4)RET (Rearranged during transfection receptor tyrosine kinase)SFK (SRC family kinases)VEGFR4 (Vascular endothelial growth factor Receptor-3)
Beyond the preview
Go deeper on JNJ-26483327.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JNJ-26483327.